Overcoming multidrug-resistance in cancer: Statins offer a logical candidate

Medical Hypotheses

Volumn 74, Issue 2, 2010, Pages 237-239

  Mehta, Narendra G ^a   Mehta, Monica ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; GERANYLTRANSFERASE; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 49; PHEROMONE; PROTEIN STE6; SIMVASTATIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EFFUSION; HUMAN; LIPID METABOLISM; METASTASIS; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; TUMOR CELL; TUMOR VASCULARIZATION; YEAST;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, BIOLOGICAL; NEOPLASMS;

ANIMALIA; MAMMALIA;

EID: 72649092760     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.09.039     Document Type: Article

References (35)

1. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Nat Rev Drug Discov 5 (2006) 219-234
2. Riordan J.R., Deuchars K., Kartner N., Alon N., Trent J., and Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316 (1985) 817-819
3. Garcia M., Jemal A., Ward E.M., et al. Global cancer facts and figures 2007 (2007), American Cancer Society, Atlanta, GA
4. Longley D.B., and Johnston P.G. Molecular mechanisms of drug resistance. J Pathol 205 (2005) 275-292
5. Glavinas H., Krajcsi P., Cserepes J., and Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1 (2004) 27-42
6. Dawson R., Kaspar J.P., and Locher P. Structure of a bacterial multidrug ABC transporter. Nature 443 (2006) 180-185
7. Ricardo S., and Lehmann R. An ABC transporter controls export of a Drosophila germ cell attractant. Science 323 (2009) 943-946
8. Hla T., and Im D.S. The ABCs of lipophile transport. Science 323 (2009) 883-884
9. Christensen P.U., Davey J., and Nielsen O. The Schizosaccharomyces pombe mam1 gene encodes an ABC transporter mediating secretion of M-factor. Mol Gen Genet 255 (1997) 226-236
10. McGrath J.P., and Varshavsky A. The yeast STE6 gene encodes a homologue of the mammalian multidrug resistance P-glycoprotein. Nature 340 (1989) 400-404
11. Raymond M., Gros P., Whiteway M., and Thomas D.Y. Functional complementation of yeast ste6 by a mammalian multidrug resistance mdr gene. Science 256 (1992) 232-234
12. van Veen H.W., Callaghan R., Soceneantu L., Sardini A., Konings W.N., and Higgins C.F. A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene. Nature 391 (1998) 291-295
13. Liu M., Bryant M.S., Chen J., et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58 (1998) 4947-4956
14. Wang E., Casciano C.N., Clement R.P., and Johnson W.W. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 61 (2001) 7525-7529
15. Wang E.J., and Johnson W.W. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy 49 (2003) 303-308
16. Morgan M.A., Sebil T., Aydilek E., Peest D., Ganser A., and Reuter C.W. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol 130 (2005) 912-925
17. Horie N., Murata H., Nishigaki Y., et al. The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett 238 (2006) 111-118
18. Kuroda J., Kimura S., Andreef M., et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukemias with diverse drug-resistance mechanisms. Brit J Haematol 140 (2008) 181-190
19. Zhang Y., Cao R., Yin F., et al. Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc 131 (2009) 5153-5162
20. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 (2009) 679-691
21. Aller S.G., Yu J., Ward A., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323 (2009) 1718-1722
22. McFadyen M.C., McLeod H.L., Jackson F.C., Melvin W.T., Doehmer J., and Murray G.I. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62 (2001) 207-212
23. Bosch I., Dunussi-Joannopoulos K., Wu R.L., Furlong S.T., and Croop J. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 36 (1997) 5685-5694
24. Loo T.W., Bartlett M.C., and Clarke D.M. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278 (2003) 39706-39710
25. Lugo M.R., and Sharom F.J. Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. Biochemistry 44 (2005) 14020-14029
26. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54 16 (1994) 4313-4320
27. Fritz G. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). Int J Oncol 27 (2005) 1401-1409
28. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., and Lippman S.M. Statins and cancer prevention. Nat Rev Cancer 5 (2005) 930-942
29. Hindler K., Cleeland C.S., Rivera E., and Collard C.D. The role of statins in cancer therapy. Oncologist 11 (2006) 306-315
30. Agarwal B., Bhendwal S., Halmos B., Moss S.F., Ramey W.G., and Holt P.R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5 (1999) 2223-2229
31. Holstein S.A., and Hohl R.J. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1 (2001) 141-149
32. Feleszko W., Mlynarczuk I., Olszewska D., et al. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 100 (2002) 111-118
33. Schmidmaier R., Baumann P., Simsek M., Dayyani F., Emmerich B., and Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104 (2004) 1825-1832
34. Schmidmaier R., Baumann P., Bumeder I., Meinhardt G., Straka C., and Emmerich B. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 79 (2007) 240-243
35. van der Spek E., Bloem A.C., Sinnige H.A., and Lokhorst H.M. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica 92 (2007) e130-e131